Across TCGA pan-cancer cohorts, ADAT3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ADAT3 data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ADAT3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ADAT3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and HNSC are the cancer types where ADAT3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	III,IV	1.000	0.676	.019	15	view →
CCRCC	DFS	Median	All	0.980	0.840	.006	7	view →
HNSC	DFS	Quartile	II,III,IV	1.000	0.857	.010	5	view →
LUAD	OS	Median	III,IV	0.896	0.333	.024	4	view →
LSCC	OS	Quartile	All	1.000	0.771	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: ADAT3 tumor-vs-normal RNA expression · all ADAT3 data types